We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04250597
Previous Study | Return to List | Next Study

Study of GNX102 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04250597
Recruitment Status : Recruiting
First Posted : January 31, 2020
Last Update Posted : March 21, 2022
Sponsor:
Information provided by (Responsible Party):
GlycoNex, Inc.

Brief Summary:

GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells. Specifically, GNX102 binds to branched Lewis B/Lewis Y (LeB/LeY) glycans, which are novel glycan structures caused by glycosylation changes in tumors. This preferential binding to branched LeB/LeY versus monomeric LeB and LeY could improve the therapeutic index by both improving selectivity for tumor cells and reducing toxicity to normal tissues.

Patients with epithelial origin cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.


Condition or disease Intervention/treatment Phase
Solid Tumor Metastatic Cancer Advanced Cancer Unresectable Solid Neoplasm Drug: GNX102 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of GNX102 in Patients With Advanced Solid Tumors
Actual Study Start Date : July 29, 2020
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: Part 1 Dose Escalation
Drug: GNX102 Dose Escalation: 21 day dosing interval
Drug: GNX102
Dose Escalation

Experimental: Part 2 Dose Escalation
Drug: GNX102 Dose Escalation: 7 day dosing interval
Drug: GNX102
Dose Escalation

Experimental: Part 3 Dose Expansion
Drug: GNX102 Dose Expansion: Selected dose level(s) and schedule(s) in expanded cohort(s)
Drug: GNX102
Dose Escalation




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: Through study completion, an average of 2 years ]
    If ≤ 1 of 6 patients has a dose limiting toxicity (DLT) after all previous dose testing the dose will be declared the Maximum Tolerable Dose (MTD).


Secondary Outcome Measures :
  1. Antitumor activity of GNX102 [ Time Frame: Through study completion, an average of 2 years ]
    To evaluate antitumor activity of GNX102 by objective radiographic assessment

  2. AUC: Area under the concentration curve of GNX102 (μg × h/mL) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the AUC Area under the concentration curve of GNX102

  3. Cmax: Maximum plasma concentration of GNX102 (μg) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the pharmacokinetics (PK) of GNX102

  4. Tmax: Time to maximum plasma concentration of GNX102 (minutes) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the pharmacokinetics (PK) of GNX102

  5. t1/2: Terminal phase half-life of GNX102 (minutes) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the pharmacokinetics (PK) of GNX102

  6. CL: Clearance of GNX102 (L/hr) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the pharmacokinetics (PK) of GNX102

  7. Vz: Apparent volume of distribution in the terminal phase of GNX102 (L) [ Time Frame: Through study completion, an average of 2 years ]
    To determine the pharmacokinetics (PK) of GNX102

  8. Number of adverse events (AEs) [ Time Frame: Through study completion, an average of 2 years ]
    Dose-limiting AEs will be used to establish the MTD and the recommended dose for phase 2 studies (RP2D)

  9. Number of toxicities [ Time Frame: Through study completion, an average of 2 years ]
    Toxicities will be used to establish the MTD and the recommended dose for phase 2 studies (RP2D)


Other Outcome Measures:
  1. Exploratory Outcome: GNX102 targeted antigens (counts) [ Time Frame: Through study completion, an average of 2 years ]
    To explore tumor expression of GNX102 targeted antigens as a biomarker to predict toxicity or response to GNX102

  2. Exploratory Outcome: Serum CA 19-9, CA 125, or CEA antigen levels (counts) [ Time Frame: Through study completion, an average of 2 years ]
    To explore biomarkers related to participant's specific cancer type (e.g. pancreas, ovarian, or colon, respectively) to predict toxicity or response to GNX102

  3. Exploratory Outcome: Anti-drug antibody (ADA) to GNX102 (counts) [ Time Frame: Through study completion, an average of 2 years ]
    To evaluate the development of anti-drug antibody (ADA) to GNX102



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

The target study population consists of adult patients with advanced solid tumors that meet all of the following criteria to be enrolled into this study:

  1. Age ≥ 18 years.
  2. Participants with histologically confirmed solid tumors with a likelihood of expression of GNX102 targeted antigens, which are limited to:

    • colorectal
    • hepatocellular
    • non-small cell lung
    • gastric
    • breast
    • bladder
    • pancreatic
    • melanoma (cutaneous, acral, or mucosal)
    • esophageal
    • prostate
    • ovarian
    • cervical
    • epithelial uterine cancers.
  3. Participant has a paraffin block of non-necrotic tumor tissue available for immunohistochemistry (IHC) analyses, to be shipped and confirmed adequate by NeoGenomics pathologist prior to initiation of treatment.
  4. Advanced, unresectable (local, regionally, recurrent not amenable to curative therapy) or metastatic disease that has no standard therapeutic option with a proven clinical benefit, are intolerant to or have refused all standard of care options with demonstrated clinical benefit.
  5. Expansion Phase only: Participant has measurable disease per response evaluation criteria in solid tumors (RECIST) v 1.1 criteria.
  6. Eastern Cooperative Group (ECOG) performance status of 0 or 1.
  7. Baseline Q-T corrected interval (QTc) interval of ≤ 480 msec using Frederica's formula.
  8. Acceptable liver function:

    • Bilirubin ≤ 1.5 times upper limit of normal
    • Aspartate transaminase (serum glutamic-oxaloacetic transaminase) [AST (SGOT)] and alanine transaminase (serum glutamic-pyruvic transaminase) [ALT (SGPT)] ≤ 3 times upper limit of normal. If liver metastases are present, then ≤ 5 x upper limits of normal (ULN) is allowed, and
    • Serum albumin ≥ 2.5 g/dL.
  9. Acceptable renal function, defined as calculated creatinine clearance > 30 mL/min per institution laboratory value.
  10. Acceptable hematologic status:

    • Hemoglobin ≥ 8 g/dL (no packed red blood cell [PRBC] transfusions allowed within 2 weeks)
    • Absolute neutrophil count (ANC) ≥ 1500 cells/mm^3 or ≥ 1.5 x 10^9/L, and
    • Platelet count ≥ 100,000 platelets/mm^3 or ≥ 100 x 10^9/L, and
    • Absolute reticulocyte count (x10^9/L) ≤ ULN.
  11. Serum haptoglobin (mg/dL) ≥ LLN.
  12. Acceptable coagulation status with fibrinogen above LLN; prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) ≤ 1.5 times upper limit of normal (may be on a stable dose of coumadin with stable INR in the therapeutic range).
  13. Life expectancy of at least 3 months.
  14. Signed Institutional Review Board (IRB)-approved informed consent.
  15. Able and willing to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations.
  16. A negative serum pregnancy test, if female of child-bearing potential.
  17. For men and women of child-bearing potential, agreement to the use of at least 1 highly effective contraceptive method(s) during the study and in the 3 months following the last dose of GNX102.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from participation in this study:

  1. Has any other malignancy not listed in Inclusion Criteria 2. Note: Participants with prior early-stage cervical cancer, basal cell carcinoma (BCC) or squamous cell carcinoma that has been successfully treated with curative intent and participant has been disease free for >2 years may be enrolled.
  2. Has a positive polymerase chain reaction (PCR) test for active COVID-19 infection or has signs or symptoms consistent with COVID-19 in the absence of a positive PCR test within 2 weeks from date of consent.
  3. Has New York Heart Association Class III or IV heart disease.
  4. History of myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, within the past 6 months.
  5. History of cerebral vascular accident or transient ischemic attack within the past 6 months.
  6. History of primary central nervous system (CNS) tumor.
  7. History of CNS metastases, unless previously treated and stable for at least 4 weeks in the absence of steroids. Participants with meningeal carcinomatosis are excluded regardless of treatment.
  8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 72 hours of start of therapy.
  9. Active, nonmalignant gastrointestinal (GI) disease requiring treatment (such as inflammatory bowel disease, Crohn's disease, colitis) that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the participant inappropriate for entry into this study.
  10. Clinical symptoms of pancreatitis within the past 28 days.
  11. Known active infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C.

    • Patients with a history of hepatitis B or C are allowed if HBV deoxyribonucleic acid (DNA) or Hep C ribonucleic acid (RNA) are undetectable. Participants with hepatocellular cancer on antiviral therapy must have DNA levels ≤ 500IU/ml.
    • Participants with a history of HBV will be monitored for HBV reactivation while on study.
  12. Pregnant or nursing women.
  13. Treatment with radiation therapy within 14 days prior to dosing with GNX102.
  14. Major surgery within 14 days prior to dosing with GNX102.
  15. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
  16. Second malignancy which is considered active or requires concurrent treatment.
  17. For participants with hepatocellular carcinoma

    • Ascites requiring more than 1 paracentesis per month
    • History of hepatic encephalopathy within 12 months of study entry
  18. History of bleeding esophageal or gastric varices within 6 months of study entry.
  19. Prior or ongoing cancer treatment, including investigational treatment within 5 half-lives or 21 days whichever is less, prior to dosing with GNX102 and 6 weeks for nitrosoureas or mitomycin C.
  20. Allergies to any excipients in GNX102 (i.e., L-histidine, sucrose, Polysorbate 80).
  21. Severe acute or chronic medical or psychiatric conditions or other laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the participant inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04250597


Contacts
Layout table for location contacts
Contact: Yu-Ting Lin +886-2-26974168 ext 138 ytlin@glyconex.com.tw
Contact: Mei-Chun Yang, PhD +886-2-26974168 ext 168 myang@glyconex.com.tw

Locations
Layout table for location information
United States, California
USC Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Diana Hanna, MD         
Principal Investigator: Diana Hanna, MD         
Hoag Cancer Center (USC) Recruiting
Newport Beach, California, United States, 92663
Contact: Diana Hanna, MD         
Principal Investigator: Diana Hanna, MD         
United States, Minnesota
Regions Cancer Care Center Recruiting
Saint Paul, Minnesota, United States, 55303
Contact: Arkadiusz Dudek, MD         
Contact       Arkadiusz.Z.Dudek@HealthPartners.com   
Principal Investigator: Arkadiusz Dudek, MD         
United States, Oregon
Providence Cancer Institute Earle A. Chiles Research Institute Recruiting
Portland, Oregon, United States, 97213
Contact: Rachel Sanborn, MD         
Principal Investigator: Rachel Sanborn, MD         
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Anthony J Olszanski, MD, RPh         
Principal Investigator: Anthony J Olszanski, MD, RPh         
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Ben George, MD         
Principal Investigator: Ben George, MD         
Sponsors and Collaborators
GlycoNex, Inc.
Investigators
Layout table for investigator information
Study Director: Mei-Chun Yang, PhD President, GlycoNex, Inc.
Layout table for additonal information
Responsible Party: GlycoNex, Inc.
ClinicalTrials.gov Identifier: NCT04250597    
Other Study ID Numbers: GNX-001
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: March 21, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms
Neoplastic Processes
Pathologic Processes